Apollo Invests €3 Billion in Bayer's Contraceptives Business

Global asset management firm Apollo Global Management has reached an agreement to invest 3 billion euros (approximately $3.43 billion) in Bayer, the German pharmaceutical and chemical giant's long-acting reversible contraceptives (LARC) business. Under the terms of the agreement, funds and affiliates managed by Apollo will acquire a minority, non-controlling stake in a newly established entity that will hold Bayer's LARC business.

According to the deal's specifics, Bayer will retain a majority stake and full operational control over the business unit within the new entity. The LARC activities will continue to be a core part of Bayer's Pharmaceuticals Division and will remain fully consolidated in the Bayer Group's financial statements. Bayer's Chief Financial Officer, Judith Hartmann, stated that this transaction represents a strategic financing solution that strengthens the company's capital structure while preserving full operational control over this core pharmaceutical business.

For Bayer, this investment is critically important for bolstering its balance sheet and managing increased liquidity requirements. Specifically, obligations related to bond maturities and ongoing litigation procedures, particularly those concerning the Roundup glyphosate herbicide, have necessitated an enhancement of the company's financial flexibility this year. The LARC business unit includes hormonal intrauterine system (IUS) products such as Mirena, Kyleena, Jaydess/Skyla, and Jadelle, which generated €1.37 billion in sales last year, growing by over 12%.

This development has been met with positive reactions in the markets. Bayer's shares saw an increase following the announcement of the deal. Such strategic partnerships allow large pharmaceutical companies to focus on their core business areas while simultaneously optimizing their capital structure. Apollo's role in this agreement reflects its mission to provide flexible and bespoke capital to a global life sciences leader.

In a broader economic context, companies continue to seek financial flexibility in the face of rising litigation costs and debt burdens. Particularly in the pharmaceutical sector, factors such as the high cost of R&D investments and expiring patents drive companies towards portfolio optimization and strategic financing solutions. Bayer's move is seen as part of its effort to address current challenges while pursuing its long-term growth strategies.

Market analysts anticipate that this step will strengthen Bayer's financial position, allowing it to focus more on future growth opportunities. The transaction is expected to close in the third quarter of 2026, subject to antitrust approvals and other customary conditions. This investment is anticipated to support Bayer's innovation capabilities and reinforce its leading position in women's health.